Telomir Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
TELO Nasdaq 2834 telomirpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Telomir Pharmaceuticals, Inc.

BC-Most Active Stocks - Jul 18th, 2025 8:32 am
Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin - Jul 18th, 2025 6:00 am
Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging - Jun 18th, 2025 7:15 am
EXCLUSIVE: Telomir Pharmaceuticals Says Preclinical Drug Candidate Prevents Premature Aging In Patient-Derived Cells From Children With Progeria - Jun 18th, 2025 7:00 am
TELO Reverses Damage in Progeria Cells - Jun 18th, 2025 6:09 am
TELO Rises on Promising Telomir-1 Preclinical Results - Jun 13th, 2025 11:58 am
Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model - Jun 11th, 2025 7:30 am
TELO Continues Trend of Significant Trial Announcements - Jun 11th, 2025 5:24 am
Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome - Jun 5th, 2025 6:30 am
EXCLUSIVE: Telomir Pharmaceuticals Lead Drug Shows Promising Signs In Animal Study For Rare Premature Aging Disorder - Jun 5th, 2025 5:41 am
TELO Data Indicates Aging Reversal Potential - Jun 5th, 2025 4:06 am
Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform - Jun 2nd, 2025 6:30 am
Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints - May 29th, 2025 6:30 am
TELO Produces Results with Exciting AMD Implications - May 29th, 2025 4:10 am
Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND - May 21st, 2025 7:00 am
EXCLUSIVE: Telomir Pharma To Raise $3 Million Via Equity Financing To Fund Its Rare Disease IND - May 21st, 2025 6:15 am
Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity - May 15th, 2025 6:00 am
TELO Announces Exciting Discovery - May 15th, 2025 5:20 am
Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia - May 7th, 2025 6:00 am
TELO Announces Promising Aging Reversal Test Results - May 7th, 2025 5:17 am